| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | BDMF; DMSFH; DMSMFH; LGMBF; MeSAdo phosphorylase; MSAP; MTAP; MTAPase; ;MTAP |
| WB Predicted band size | 31 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human MTAP |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于MTAP抗体的3篇参考文献的简要总结(文献信息为模拟示例，仅供参考)：
1. **文献名称**：*MTAP deletion in cancers: A potential therapeutic target*
**作者**：Smith J, et al.
**摘要**：该研究分析了多种肿瘤中MTAP基因缺失的频率，发现其缺失与CDKN2A缺失高度相关。通过免疫组化(使用MTAP抗体)验证了MTAP蛋白表达缺失在胰腺癌和胶质瘤中的临床意义，提示其可能作为合成致死疗法的靶点。
2. **文献名称**：*Immunohistochemical loss of MTAP as a diagnostic marker for mesothelioma*
**作者**：Brown R, et al.
**摘要**：研究评估了MTAP抗体在间皮瘤诊断中的应用。结果显示，MTAP蛋白表达缺失(通过免疫组化检测)在恶性间皮瘤中占比约60%，且与BAP1缺失存在互补性，可作为辅助诊断标志物。
3. **文献名称**：*MTAP deficiency creates metabolic vulnerabilities in cancer*
**作者**：Zhang Y, et al.
**摘要**：本文利用MTAP抗体通过Western blot和免疫荧光技术，证实MTAP缺失的肿瘤细胞依赖特定代谢通路生存。研究提出MTAP缺失导致甲基硫腺苷(MTA)累积，可能成为化疗增敏的生物标志物。
注：以上文献信息为示例性内容，实际引用时需核对真实文献来源及准确性。建议通过PubMed或Web of Science以“MTAP antibody”或“MTAP immunohistochemistry”为关键词查找最新研究。
**Background of MTAP Antibodies**
Methylthioadenosine phosphorylase (MTAP) is a key enzyme in the purine salvage pathway, catalyzing the conversion of methylthioadenosine (MTA) into adenine and methionine. The *MTAP* gene is located on chromosome 9p21.3. a region frequently deleted in cancers such as glioblastoma, pancreatic adenocarcinoma, and non-small cell lung cancer. This deletion often co-occurs with loss of the tumor suppressor gene *CDKN2A*, making MTAP deficiency a common feature in malignancies with 9p21 loss.
MTAP antibodies are critical tools for detecting MTAP protein expression in research and diagnostics. Loss of MTAP protein, detected via immunohistochemistry (IHC) or Western blotting, serves as a surrogate marker for 9p21 deletions, aiding cancer subtyping and prognostication. Additionally, MTAP-deficient tumors exhibit metabolic vulnerabilities, such as heightened dependence on protein arginine methyltransferase 5 (PRMT5), which can be therapeutically targeted. MTAP antibodies thus play a role in identifying patients eligible for PRMT5 inhibitor therapies or other synthetic lethal approaches.
Recent studies also explore MTAP's immunomodulatory roles, linking its loss to altered adenosine signaling and immune evasion. As research advances, MTAP antibodies remain vital for unraveling MTAP's biological functions and translating its clinical relevance into targeted cancer treatments.
×
